Скачать или смотреть First-in-human study of INCA32459, a LAG-3/PD-1 bsAb in advanced cancers

Jesus Fuentes-Antras, MD, NEXT Oncology Madrid, Hospital Universitario Quirónsalud Madrid, Madrid, Spain, discusses the first-in-human Phase I study of INCA32459 (NCT05577182), a bispecific antibody (bsAb) targeting PD-1 and LAG-3 in patients with select advanced malignancies. INCA32459 demonstrated a manageable safety profile consistent with immune checkpoint inhibitors, linear pharmacokinetics, and evidence of T-cell activation. Early efficacy was observed, including complete and partial responses in heavily pretreated tumors. This interview took place at 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress in London, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.